ClinicalTrials.gg
RecruitingNCT02468024STABLE-MATESUpdated Nov 16, 2026

JoLT-Ca Sublobar Resection (SR) Versus Stereotactic Ablative Radiotherapy (SAbR) for Lung Cancer

A Phase 3 interventional study of Lung Surgery and Radiation therapy in Non-Small Cell Lung Cancer, sponsored by University of Texas Southwestern Medical Center. Recruiting at 50 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by University of Texas Southwestern Medical Center · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jul 2015; still recruiting 11 years 4 months later.
Updated Nov 16, 2026Site recruiting status changedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
272
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 22 studies in Carcinoma, Non-Small-Cell Lung by University of Texas Southwestern Medical Center — 2 open to participants now, 4 under way, 1 of them phase 3. Carcinoma, Non-Small-Cell Lung · University of Texas Southwestern Medical Center.

Planned enrollment
2nd of 22
272 · median 24
Started
2015
with 2 others
Phase 3
2 of 22
1 open now
Registered
10th of 22
by date

Among the 22 studies in Carcinoma, Non-Small-Cell Lung by University of Texas Southwestern Medical Center, this one is the 2nd largest by planned enrollment, is one of 3 that started in 2015, is one of 2 in phase 3, and was the 10th registered.

Carcinoma, Non-Small-Cell Lung

7,639 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

2 of the 22 studies in Carcinoma, Non-Small-Cell Lung by University of Texas Southwestern Medical Center are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 1,324 Carcinoma, Non-Small-Cell Lung studies recruiting now, 987 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies in Carcinoma, Non-Small-Cell Lung by University of Texas Southwestern Medical Center, or all of them as a file.
02

Study summary

To Determine if SAbR improves survival over SR in High Risk Operable Stage I NSCLC

Read the detailed description

Stereotactic Ablative Radiotherapy has been shown in single institution phase II and matched cohort studies to be effective at controlling primary early lung cancer. Recent pooled analysis of both the STARS and ROSEL randomized trials comparing SABR versus lobectomy have shown a significantly improved 3-year survival with SABR, giving further impetus for successful completion of a randomized trial .

Pre-randomized trial- Patients will be screened and pre-randomized to either SR or SAbR. Informed consent will be obtained after patients are made aware of the randomized assignment. Despite pre-randomization prior to consent, patients maintain their right to accept or decline any/all study activities. Only consenting patients will be allowed to participate in study activities, including observation after either randomized treatments or observation after standard of care treatment, while those declining consent will be managed by their physician(s) off study.Patients will be accrued and followed for a minimum of 2-years after treatment.

03

Conditions studied

  • Non-Small Cell Lung Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

1.1 Age > 18 years.

1.2 /Zubrod performance status (PS) 0, 1, or 2 (reference Appendix C).

1.3 Radiographic findings consistent with non-small cell lung cancer, including lesions with ground glass opacities with a solid component of 50% or greater.

1.4 The primary tumor in the lung must be confirmed non-small cell lung cancer within 180 days prior to randomization.

1.5 Tumor ≤ 4 cm maximum diameter, including clinical stage IA and selected IB by PET or PET integrated with a simultaneous CT scan (PET-CT) of the chest and upper abdomen performed within 180 days prior to randomization (reference Appendix A \& B). Repeat imaging within 90 days prior to randomization is recommended for re-staging but is not required based on institutional norms.

1.6 All clinically suspicious mediastinal N1, N2, or N3 lymph nodes (> 1 cm short-axis dimension on CT scan and/or positive on PET scan) confirmed negative for involvement with NSCLC by one of the following methods: mediastinoscopy, anterior mediastinotomy, EUS/EBUS guided needle aspiration, CT-guided, video-assisted thoracoscopic or open lymph node biopsy within 180 days of randomization.

1.7 Tumor verified by a thoracic surgeon to be in a location that will permit sublobar resection.

1.8 Tumor located peripherally within the lung. NOTE: Peripheral is defined as not touching any surface within 2 cm of the proximal bronchial tree in all directions. See bronchial tree diagram below. Patients with non-peripheral (central) tumors are NOT eligible.

1.9 No evidence of distant .

1.10 Availability of pulmonary function tests (PFTs - spirometry, DLCO, +/- arterial blood gases) within 180 days prior to registration. Patients with tracheotomy, etc, who are physically unable to perform PFTs (and therefore cannot be tested for the Major criteria in 3.1.11 below) are potentially still eligible if a study credentialed thoracic surgeon documents that the patient's health characteristics would otherwise have been acceptable for eligibility as a high risk but nonetheless operable patient (in particular be eligible for sublobar resection).

1.11 To define eligibility of patients being at high risk for surgery, certain criteria must be met.

Any one (1) of the following major criteria will define the high risk status for eligibility:

Major Criteria

  • ≤ 50% predicted (pre-bronchodilator value)
  • DLCO ≤ 50% predicted (pre-bronchodilator value)
  • Study credentialed thoracic surgeon believes the patient is potentially operable but that a lobectomy or pneumonectomy would be poorly tolerated by the patient for tangible or intangible reasons. The belief must be declared and documented in the medical record prior to randomization.

If any of the major criteria are met, the patient is eligible based on high risk for surgery and minor criteria do not need to be considered. However, if no major criteria is met, at least two (2) minor criteria being met will also define eligibility for meeting the high risk status.

Any two (2) of the following minor criteria will define the high risk status for eligibility:

  • Minor Criteria
  • Age ≥75
  • FEV1 51-60% predicted (pre-bronchodilator value)
  • DLCO 51-60% predicted (pre-bronchodilator value)
  • Pulmonary hypertension (defined as a pulmonary artery systolic pressure greater than 40mm Hg) as estimated by echocardiography or right heart catheterization
  • Poor left ventricular function (defined as an of 40% or less)
  • Resting or Exercise Arterial pO2 ≤ 55 mm Hg or SpO2 ≤ 88%
  • pCO2 > 45 mm Hg
  • Modified Medical Research Council (MMRC) Dyspnea Scale ≥ 3.

1.12 No prior intra-thoracic radiation therapy for previously identified intra-thoracic primary tumor (e.g. previous lung cancer) on the ipsilateral side. NOTE: Previous radiotherapy as part of treatment for head and neck, breast, or other non-thoracic cancer is permitted to the ipsilateral side so long as possible radiation fields would not overlap. NOTE: Radiotherapy to the contralateral lung is allowed so long as it was completed more than 3 years prior to randomization and there is no overlap of radiation fields.

1.13 Previous chemotherapy, radiotherapy, or surgical resection specifically for the lung cancer being treated on this protocol is NOT permitted.

1.14 No prior lung resection on the ipsilateral side.

1.15 Non-pregnant and non-lactating. Women of must have a negative urine or serum pregnancy test prior to registration. Peri-menopausal women must be amenorrheic > 12 months prior to registration to be considered not of childbearing potential.

1.16 No prior invasive , unless disease-free for ≥ 3 years prior to registration (exceptions: non-melanoma skin cancer, in-situ cancers).

1.17 Ability to understand and sign a written .

Exclusion criteria

2.0 Exclusion Criteria

2.1 Age \<18

2.2 /Zubrod performance status (PS) greater than 3.

2.3 Radiographic findings with ground glass opacities and less than 50% solid component will be excluded.

2.4 The primary tumor in the lung, confirmed non-small cell lung cancer greater than 180 days prior to randomization.

2.5 Tumor > 5 cm maximum diameter, including clinical stage IA and selected IB by PET or PET integrated with a simultaneous CT scan (PET-CT) of the chest and upper abdomen and/or performed greater than 180 days prior to randomization.

2.6 Lymph node biopsy greater than 180 days prior to randomization.

2.7 Thoracic surgeon confirms unable to remove tumor with sublobar resection.

2.8 Tumor located non-peripheral (central) region of lung (see bronchial tree diagram in 3.1.8).

2.9 Evidence of distant .

2.10 Pulmonary function test (PFT - spirometry, DLCO, +/- arterial blood gases) greater than 180 days prior to registration. Patients physically unable to perform PFT's, such as patients with tracheotomy, that do not have written documentation from study credentialed thoracic surgeon stating eligibility.

2.11 Patients that do not meet either Major criteria or Minor criteria.

2.12 Prior intra-thoracic radiation therapy on ipsilateral side. Radiotherapy to the contralateral lung completed less than 3 years prior to randomization, with radiation field overlap.

2.13 Prior chemotherapy, radiotherapy, or surgical resection specifically for the lung cancer being treated on this protocol.

2.14 Prior lung resection on the ipsilateral side.

2.15 Pregnant and lactating women.

2.16 Prior invasive and less than 3 years disease free prior to registration (unless non-melanoma skin cancer, in-situ cancers).

2.17 Unable to understand and/ or sign a written .

Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
272 participants (estimated)

Study arms

  • Active comparator
    Arm 1 lung surgery

    Sublobar Resection (SR)

    Procedure: Lung Surgery

  • Experimental
    Arm 2 radiation therapy

    Stereotactic Ablative Radiotherapy (SAbR)

    Radiation: Radiation therapy

Interventions

  • ProcedureLung Surgery

    Sublobar Lung Resection

    Also known as: SR

  • RadiationRadiation therapy

    Stereotactic Ablative Radiotherapy, 54 Gy in 3 fractions

    Also known as: SAbR

06

What researchers measure

Primary outcomes

  1. overall survival

    To test the hypothesis that the 3-year overall survival in high risk operable patients with Stage I NSCLC is greater in patient who undergo SAbR as compared to standard sublobar resection (SR).

    Time frame: 3 years

Secondary outcomes

  1. progression free survival

    survival at 5-years for Stage I NSCLC who undergo SR or SAbR.

    Time frame: 5 years

  2. toxicity as assessed toxicity using the Common Toxicity Criteria

    toxicity using the Common Toxicity Criteria

    Time frame: 3 years

07

Study locations

11 of 50 sites recruiting
  • UCSD
    La Jolla, California 92023, United States
    Completed

    Not enrolling at this site — choose another above.

  • University of Colorado/Memorial
    Aurora, Colorado 80045, United States
    Completed

    Not enrolling at this site — choose another above.

  • Penrose Cancer Center
    Colorado Springs, Colorado 80907, United States
    Completed

    Not enrolling at this site — choose another above.

  • Boca Raton Regional Hospital
    Boca Raton, Florida 33486, United States
    Completed

    Not enrolling at this site — choose another above.

  • Curtis and Elizabeth Anderson Cancer
    Savannah, Georgia 31404, United States
    Recruiting
    • Aaron Pederson, MD · Contact912-350-8490
  • University of Iowa
    Iowa City, Iowa 52242, United States
    Terminated

    Not enrolling at this site — choose another above.

  • University of Kansas Medical Center
    Kansas City, Kansas 66160, United States
    Completed

    Not enrolling at this site — choose another above.

  • University of Kentucky Health Care
    Lexington, Kentucky 40536-0093, United States
    Completed

    Not enrolling at this site — choose another above.

  • University of Louisville Physicians
    Louisville, Kentucky 40202, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Ochsner Medical Center
    New Orleans, Louisiana 70121, United States
    Completed

    Not enrolling at this site — choose another above.

  • Luminis Health Research Institute
    Annapolis, Maryland 21401, United States
    Completed

    Not enrolling at this site — choose another above.

  • University of Maryland Medical Center
    Baltimore, Maryland 21201, United States
    Completed

    Not enrolling at this site — choose another above.

  • Boston Medical Center
    Boston, Massachusetts 02118, United States
    Completed

    Not enrolling at this site — choose another above.

  • Henry Ford Health System
    Detroit, Michigan 48202-2689, United States
    Completed

    Not enrolling at this site — choose another above.

  • Beaumont
    Royal Oak, Michigan 48073, United States
    Completed

    Not enrolling at this site — choose another above.

  • Mayo Clinic Rochester
    Rochester, Minnesota 55905, United States
    Completed

    Not enrolling at this site — choose another above.

  • Meridian Health System
    Neptune City, New Jersey 07753, United States
    Recruiting
  • New York University Langone Medical Center
    New York, New York 10016, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • SUNY - Upsate Medical Centre
    Syracuse, New York 13210, United States
    Recruiting
  • University of North Carolina
    Chapel Hill, North Carolina 27599, United States
    Completed

    Not enrolling at this site — choose another above.

  • Wake Forest Baptist Health
    Winston-Salem, North Carolina 27157, United States
    Completed

    Not enrolling at this site — choose another above.

  • University of Cincinnati
    Cincinnati, Ohio 45267, United States
    Completed

    Not enrolling at this site — choose another above.

  • Case Western (University Hospitals Case Medical Center)
    Cleveland, Ohio 44106, United States
    Completed

    Not enrolling at this site — choose another above.

  • Cleveland Clinic
    Cleveland, Ohio 44195, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Ohio State University Wexner Medical Center
    Columbus, Ohio 43210, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Providence Health & Services/Oregon Clinic
    Portland, Oregon 97213, United States
    Completed

    Not enrolling at this site — choose another above.

  • Thomas Jefferson University
    Philadelphia, Pennsylvania 19107, United States
    Completed

    Not enrolling at this site — choose another above.

  • Allegheny
    Pittsburgh, Pennsylvania 15212, United States
    Recruiting
  • UPMC Health System
    Pittsburgh, Pennsylvania 15234, United States
    Completed

    Not enrolling at this site — choose another above.

  • Mount Nittany
    State College, Pennsylvania 16803, United States
    Completed

    Not enrolling at this site — choose another above.

  • Lifespan Oncology Clinical Research
    Providence, Rhode Island 02903, United States
    Completed

    Not enrolling at this site — choose another above.

  • University of Tennessee Health Science Center
    Memphis, Tennessee 38163, United States
    Completed

    Not enrolling at this site — choose another above.

  • Cardiothoracic and Vascular Surgeons
    Austin, Texas 78756, United States
    Completed

    Not enrolling at this site — choose another above.

  • University of Texas Southwestern Medical Center
    Dallas, Texas 75390, United States
    Recruiting
    • Robert Timmerman, MD · Contact214-645-8525
    • Robert Timmerman, MD · Principal investigator
  • Intermountain Medical Center
    Salt Lake City, Utah 84107, United States
    Completed

    Not enrolling at this site — choose another above.

  • University of Virginia Health System
    Charlottesville, Virginia 22901, United States
    Completed

    Not enrolling at this site — choose another above.

  • Inova Fairfax Medical Campus
    Falls Church, Virginia 22042, United States
    Completed

    Not enrolling at this site — choose another above.

  • Swedish Cancer Institute
    Seattle, Washington 98104, United States
    Completed

    Not enrolling at this site — choose another above.

  • Medical College of Wisconsin
    Milwaukee, Wisconsin 53226, United States
    Completed

    Not enrolling at this site — choose another above.

  • Clement Zablocki VA Medical Center
    Milwaukee, Wisconsin 53295, United States
    Completed

    Not enrolling at this site — choose another above.

  • St. Vincent's Hospital Melbourne
    Fitzroy, Melbourne 3065, Australia
    Recruiting
  • St. Vincent's/Peter Mac
    Fitzroy, Victoria 3065, Australia
    Recruiting
  • Barwon Health - Uni Hospital Geelong
    Geelong, Victoria 3220, Australia
    Completed

    Not enrolling at this site — choose another above.

  • Trillium Health Partners
    Mississauga, Canada L5M 2N1, Canada
    Completed

    Not enrolling at this site — choose another above.

  • Sunnybrook Health Sciences Centre
    Toronto, Canada M4N 3M5, Canada
    Completed

    Not enrolling at this site — choose another above.

  • Ottawa Hospital Cancer Center
    Ottawa, Ontario KIH8L6, Canada
    Recruiting
  • UHN-Toronto
    Toronto, Ontario M5G2C4, Canada
    Recruiting
    • Andrew Pierre, MD · Contact416-340-3131
    • Jennifer Lister · Contact416-340-3131
  • Lawson Health Science Center
    London, Ontario, Canada N6C 2R5, Canada
    Recruiting
    • Richard Malthaner · Contact519-646-6005
    • Deb Lewis · Contact519-646-6005
  • CHUM
    Montreal, Quebec 26214, Canada
    Recruiting
    • Moishe Liberman, MD · Contact514 890-8000
    • Adeline Jouquan · Contact514 890-8000
  • The James Cook University Hospital
    Middlesbrough, TS4 2BW, United Kingdom
    Active, not recruiting

    Not enrolling at this site — choose another above.

08

References and documents

Publications

  • Elbanna M, Shiue K, Edwards D, Cerra-Franco A, Agrawal N, Hinton J, Mereniuk T, Huang C, Ryan JL, Smith J, Aaron VD, Burney H, Zang Y, Holmes J, Langer M, Zellars R, Lautenschlaeger T. Impact of Lung Parenchymal-Only Failure on Overall Survival in Early-Stage Lung Cancer Patients Treated With Stereotactic Ablative Radiotherapy. Clin Lung Cancer. 2021 May;22(3):e342-e359. doi: 10.1016/j.cllc.2020.05.024. Epub 2020 Jun 2. PubMed 32736936 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2015 (actual). Primary completion is estimated for Dec 2028, 161 months after the start.

Of 109 non-industry phase 3 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 81 months of starting (the median), counting those still running; a quarter within 49 and three quarters within 129. This study's planned 161 months is above that.

Counting every sponsor, half of 423 studies reached it within 45 months; a quarter within 30 and three quarters within 69.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 1, 2015
First posted
Jun 10, 2015
StartActual
Jul 2015
Primary completionEst.
Dec 2028
CompletionEst.
Dec 2028
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
2 sites changed recruiting status (2 now completed)
Show 2 sites
  • Luminis Health Research Institute · Annapolis, United StatesActive, not recruiting→Completed
  • Barwon Health - Uni Hospital Geelong · Geelong, AustraliaRecruiting→Completed
Nov 16, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • Barwon Health - Uni Hospital Geelong · Geelong, AustraliaContact removed k•••@barwonhealth.org.au · •••1033Contact removed k•••@barwonhealth.org.auContact removed (no phone or email listed)
Nov 16, 2026
Show all 1 update
  1. Nov 16, 2026
    2 sites changed recruiting status (2 now completed)
    Show 2 sites
    • Luminis Health Research Institute · Annapolis, United StatesActive, not recruiting→Completed
    • Barwon Health - Uni Hospital Geelong · Geelong, AustraliaRecruiting→Completed
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Barwon Health - Uni Hospital Geelong · Geelong, AustraliaContact removed k•••@barwonhealth.org.au · •••1033Contact removed k•••@barwonhealth.org.auContact removed (no phone or email listed)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT02468024
Responsible party
Robert Timmerman (MD, University of Texas Southwestern Medical Center) — Principal investigator
First posted
Jun 10, 2015
Start date
Jul 2015
Primary completion
Dec 2028 (estimated)
Completion
Dec 2028 (estimated)
Last update
Nov 16, 2026

Study contacts

Sarah Neufeld, MBA
Contact
sarah.hardee@UTSouthwestern.edu
214-645-8525
Robert Timmerman, MD
principal investigator · UTSW Medical Center

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion